In a dramatic escalation of a high-stakes biopharma showdown, Pfizer Inc. has filed suit in Delaware Chancery Court to stop Metsera from backing out of their multibillion-dollar merger, accusing Novo Nordisk of orchestrating an “old-fashioned bribe” to derail the deal and crush future competition in the booming weight-loss drug market. Pfizer’s lawsuit, filed Friday—the same Pfizer Sues Metsera to block $9B Novo Nordisk offer, calling it an “old-fashioned bribe” attempt.